CSIMarket Company Name, Ticker, Customers, else..
 
Innate Pharma Sa  (NASDAQ: IPHA)
Other Ticker:  
 
 
Price: $2.0001 $-0.02 -0.985%
Day's High: $2.0444 Week Perf: -0.49 %
Day's Low: $ 2.00 30 Day Perf: 3.1 %
Volume (M): 2 52 Wk High: $ 3.51
Volume (M$): $ 4 52 Wk Avg: $2.16
Open: $2.00 52 Wk Low: $1.29



 Market Capitalization (Millions $) 168
 Shares Outstanding (Millions) 84
 Employees 179
 Revenues (TTM) (Millions $) 69
 Net Income (TTM) (Millions $) -8
 Cash Flow (TTM) (Millions $) 94
 Capital Exp. (TTM) (Millions $) 0

Innate Pharma Sa
Innate Pharma SA is a biotechnology company based in France. The company focuses on discovering and developing therapeutic antibodies for the treatment of cancer and inflammatory diseases. Innate Pharma's research is centered around natural killer (NK) cell biology and tumor microenvironment.

The company's proprietary technology platform, called IPH4102, targets the KIR3DL2 receptor, which is expressed in various hematological malignancies. Innate Pharma is also involved in developing other antibodies targeting immune checkpoints, as well as modulating the tumor microenvironment to enhance immune responses against cancer.

Innate Pharma collaborates with various pharmaceutical companies and academic institutions to advance its research and development programs. The company has a pipeline of product candidates in different stages of clinical development, including monotherapy and combination therapies.

Overall, Innate Pharma aims to leverage its expertise in immune biology to develop innovative treatments for patients with cancer and inflammatory diseases.


   Company Address: 117, Avenue de Luminy Marseille 13009
   Company Phone Number: 4 30 30 30 30   Stock Exchange / Ticker: NASDAQ IPHA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMGN        2.12% 
BIIB        2% 
EXEL        0.24% 
GILD   -3.3%    
MOLN   -4.89%    
NVAX        5.81% 
• View Complete Report
   



Creative Medical Technology Holdings Inc

A shortfall of $-1.09 per Share at the CELZ in fourth quarter of 2024 earnings season

For the fourth quarter of 2024 earnings season company lost money of $-1.09 per share compare to $-1.19 a year before and increased shortfall from $-0.75 per share from the previous quarter. The revenue remained unscathed to $0.00 million from $0.00 million in the corresponding quarter a year before and sequentially from $0.00 million.

Repligen Corp

The Biotechnology and Pharmaceuticals company reported that revenue went up modest, in the financial fourth quarter of 2024

For the October to December 31 2024 fiscal time-frame company increased a loss per share of $-0.60 per share compare to $-0.29 a year prior and grew loss from $-0.01 per share from the previous reporting season. The Revenue grew softly by 0.556 % to $167.55 million from $166.62 million in the similar reporting season a year prior and sequentially revenue advanced by 8.185 % from $154.87 million. Repligen Corps' resists theBiotechnology and Pharmaceuticals sectors trend and posts revenue growth , as nearly all of the Biotechnology and Pharmaceuticals sector contemporaries, booked business reduction during the matching period.

Atyr Pharma Inc

The evolving business from the Biotechnology and Pharmaceuticals industry the ATYR reported the most recent fiscal period, numbers

The Biotechnology and Pharmaceuticals sector experts begin to analyze the fourth quarter of 2024 performance. Now those experts follow operating deficit of $-15.82 million, from the company, as it has not specified any revenue so far, for the respective October to December 31 2024 reporting season.

Sutro Biopharma Inc

The Diminishing Returns have expanded to $-0.70 at the Biotechnology and Pharmaceuticals company in the fiscal interval closing December 31 2024

Sutro Biopharma Inc disclosed disastrous fourth quarter of 2024 financial report, where Revenue faded by -86.978 % to $14.81 million and a shortfall per share has widen at $-0.70, from the comparable reporting season a year prior.

Candel Therapeutics Inc

The Biotechnology and Pharmaceuticals company caused good story for the investors, exhibiting a significant growth in financial interval closing Dec 31 2024 with operating shortfall of $-8.141 million

The investors haven't hoped for any moderations at the revenue throughout the the October to December 31 2024 reporting cycle at the CADL. Yet, shareholders pay very near attention to the company's operating shortfall which has been at $-8.141 million, in the same period.










Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com